--- title: "AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained" type: "News" locale: "en" url: "https://longbridge.com/en/news/296085001.md" description: "Bank of America Securities analyst Sachin Jain maintained a Buy rating on AstraZeneca with a 16,500 GBp price target. Despite the Phase III failure of volrustomig, Jain argues that the company's strong oncology pipeline, including key readouts like CAMBRIA-1 and positive data for Opathys plus Tagrisso, offsets this setback. Jefferies also maintained a Buy rating with a £175 target." datetime: "2026-08-17T09:05:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296085001.md) - [en](https://longbridge.com/en/news/296085001.md) - [zh-HK](https://longbridge.com/zh-HK/news/296085001.md) generator: "portal-rs" --- # AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca, with a price target of p16,500.00. ### Summer Sale - Claim 70% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Sachin Jain has given his Buy rating due to a combination of factors that, in his view, outweigh the setback from the volrustomig Phase III failure. While he acknowledges that the discontinuation of eVOLVE-Lung02 highlights renewed pipeline risk and reinforces investor concerns around AstraZeneca’s bispecific oncology strategy, he emphasizes that this was a high-risk asset already viewed cautiously and not central to the core equity story. He notes that AstraZeneca still has multiple late-stage programs and life-cycle management opportunities that underpin long-term value, particularly key readouts such as CAMBRIA-1 and the Farxiga heart failure/CKD expansion. Jain also highlights the positive Phase III data for Opathys plus Tagrisso in MET-driven EGFR-mutant lung cancer as incremental upside within the lung cancer franchise. On balance, he believes the oncology pipeline, upcoming catalysts, and fundamental earnings power support maintaining a Buy rating, with the price target kept unchanged at 16,500 GBp ($165.00). In another report released on August 7, Jefferies also maintained a Buy rating on the stock with a £175.00 price target. ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md) - [Key facts: LSE:AZN Zegfrovy buy; SANOVO PFS; Wan Ling Martello named](https://longbridge.com/en/news/297611733.md) - [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md) - [AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value](https://longbridge.com/en/news/296923180.md) - [HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso extends PFS in China Phase III SANOVO lung cancer trial](https://longbridge.com/en/news/297475889.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**